Novel selective glucocorticoid receptor modulator GRM-01 demonstrates dissociation of anti-inflammatory effects from adverse effects on glucose and bone metabolism
GRM-01 displays a favorable preclinical pharmacologic profile consistent with a SEGRAM, and based on this is currently in Phase 1 development.
Authors
- Andrew Lockhart (ORCID: https://orcid.org/0000-0002-8082-846X)
- Stephanie Hennen (ORCID: https://orcid.org/0000-0002-2734-9734)
- Feras Khalil (ORCID: https://orcid.org/0000-0003-4419-4727)
- Florian Jakob (ORCID: https://orcid.org/0009-0007-8522-5047)
- M. Gautrois
Institutions
- Grünenthal Group (Germany) (DE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.3389/fphar.2025.1542351
- Citations
- 6
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 10.90